Rubric Capital Management (New York)’s Sutro Biopharma STRO Stock Holding History

Rubric Capital Management (New York)’s Portfolio STRO Stock Details STRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-334,481	Closed	-$14.3M	–	71
2023 Q4	$14.3M	Hold	334,481	–	–	0.3%	43
2023 Q3	$11.6M	Sell	334,481 -70,393	-17%	-$3.07M	0.44%	48
2023 Q2	$18.8M	Sell	404,874 -31,175	-7%	-$1.55M	0.81%	36
2023 Q1	$20.1M	Buy	436,049 +114,862	+36%	+$7.29M	0.52%	43
2022 Q4	$26M	Buy	321,187 +181,187	+129%	+$12.6M	1.13%	29
2022 Q3	$7.77M	Buy	140,000 +50,000	+56%	+$2.96M	0.39%	53
2022 Q2	$4.69M	Buy	+90,000	New	+$5.03M	0.25%	64

Other funds holding STRO

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Rubric Capital Management (New York)'s STRO Position: Q1 2024 in Review

Rubric Capital Management (New York) sold out of Sutro Biopharma (STRO) in Q1 2024, closing a stake of 334,481 shares — an estimated $14.3M sold.

Rubric Capital Management (New York) first reported a position in STRO in Q2 2022 and held it in 7 quarters. The position peaked at $26M in Q4 2022. 117 funds tracked by Wall St. Rank hold STRO as of Q1 2024.

Rubric Capital Management (New York) reported no remaining Sutro Biopharma position as of Q1 2024 after selling out during the quarter.
Rubric Capital Management (New York) sold 334,481 Sutro Biopharma shares in Q1 2024, an estimated $14.3M.
Rubric Capital Management (New York) first reported a position in Sutro Biopharma in Q2 2022 and held it in 7 quarters.
Rubric Capital Management (New York)'s Sutro Biopharma position peaked at $26M in Q4 2022.
117 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2024.

Based on Rubric Capital Management (New York)'s 13F filing for Q1 2024, filed 10 May 2024.